Avalyn Pharma Inc. (AVLN) News
Follow Avalyn Pharma Inc. (AVLN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: AP02 Phase 1 PK results and AURA Phase 2 enrollment
Avalyn Pharma Inc (NASDAQ:AVLN) reported Phase 1 data for nebulized AP02 showing higher lung and lower systemic exposure than oral nintedanib, and is now enrolling patients in the AURA Phase 2 IPF trial as recruitment an
NEWS | Sep 28, 2026, 11:05 AM UTC
M
Avalyn Pharma publishes Phase 1 AP02 data; Phase 2 topline late 2027
Avalyn Pharma said Phase 1 AP02 data showed higher predicted lung exposure with lower systemic exposure versus oral nintedanib, and that Phase 2 AURA enrollment is on track for topline data expected late 2027.
EQUITY | Sep 21, 2026, 01:03 PM UTC
L
AVLN - Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
AVLN - Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
NEWS | Sep 21, 2026, 01:01 PM UTC
L
AVLN - Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
AVLN - Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
NEWS | Sep 16, 2026, 08:01 PM UTC
L
AVLN: Inhaled therapies with strong IP aim to transform pulmonary fibrosis treatment and market reach
Focused on inhaled therapies for pulmonary fibrosis, the company leverages a patented nebulizer and strong IP to address major unmet needs in a large market. Lead candidates show improved tolerability and efficacy, with
NEWS | Sep 14, 2026, 07:51 PM UTC
L
AVLN: Inhaled therapies targeting pulmonary fibrosis show promise for better efficacy and tolerability
The company is advancing three inhaled therapies for pulmonary fibrosis, leveraging a patented nebulizer to address major tolerability barriers and unlock a large underserved market. Lead programs show improved lung expo
NEWS | Sep 14, 2026, 07:02 PM UTC
L
Avalyn shares in silico AP01 lung distribution modeling
Avalyn presented data at ERS Congress 2026 on AP01 lung distribution and a patient-centered pulmonary fibrosis trial design. In silico modeling predicted robust AP01 distribution in healthy and fibrotic lungs, including
GEOPOLITICS | Sep 08, 2026, 12:08 PM UTC
L
Avalyn management to participate in Morgan Stanley Global Healthcare conference
Avalyn Pharma Inc. will hold management participation in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, per the company’s announcement.
EQUITY | Sep 08, 2026, 12:07 PM UTC
H
AVLN - Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient -Centered Trial Design in Pulmonary Fibro
AVLN - Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient -Centered Trial Design in Pulmonary Fibrosis
GEOPOLITICS | Sep 08, 2026, 12:00 PM UTC
L
AVLN - Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
AVLN - Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
EQUITY | Sep 08, 2026, 12:00 PM UTC
L
AVLN to present multiple updates at ERS International Congress 2026
Avalyn (AVLN) announces multiple presentations at the European Respiratory Society International Congress 2026, according to TradeXchange Newsdesk.
EQUITY | Aug 24, 2026, 08:01 PM UTC
L
Avalyn Reports Q2 2026 Financial Results
Avalyn reports second quarter 2026 financial results and recent business highlights
EARNINGS | Aug 12, 2026, 12:01 PM UTC